A stability indicating simultaneous dual wavelength UV–HPLC method for the determination of potential impurities in fampridine active pharmaceutical ingredient
Authors:
- Saji ThomasSTSaji Thomas
- Sanjeev ShandilyaSSSanjeev Shandilya
- Amber BhartiABAmber Bharti
- Ashutosh AgarwalAAAshutosh Agarwal
- 1 January 2012
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 58, 136-140
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trialClinical Therapeutics, 2009
- Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up studyClinical Therapeutics, 2009
- Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (fampridine-sr) in subjects with chronic, incomplete spinal cord injury 11A commercial party with a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit on the author or 1 or more of the authors.Archives of Physical Medicine and Rehabilitation, 2004